

# Effectiveness and safety of burosumab in an Early Access Program: a study of UK adults with X-linked hypophosphataemia

<b>Submission date</b> 31/07/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 01/08/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 20/02/2026	<b>Condition category</b> Genetic Diseases	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

X-linked hypophosphataemia (XLH) is a rare, severe, lifelong disease where phosphate is lost from the blood via the kidneys in the urine, and is at lower levels than the body requires for healthy bone and muscle development. Patients can have slowed growth, short stature, limb deformities, pain and other health problems despite conventional treatment with phosphate and vitamin D. Consequently, their quality of life can be very bad. However, a recently available treatment (burosumab) can help; this medicine was made available to patients in an Early Access Program in the UK. Because it was the first time that adult patients had been given burosumab outside a clinical trial, this is a good opportunity to see how well the medicine works and learn about symptoms, medications and side effects that patients may experience.

### Who can participate?

Patients aged 18 years or over who received burosumab through the Kyowa Kirin Early Access Programme for the treatment of XLH

### What does the study involve?

Participants' medical records will be reviewed and relevant information collected by their normal care team. This includes basic patient details, medical history and medications, as well as information about their XLH symptoms and blood test results during the time they were taking burosumab. No change is made to patients' care as part of this study, the period being studied is in the past. Participants will be informed about the study beforehand and given the opportunity to opt out, but all participants from the burosumab Early Access Programme can take part in this study.

### What are the possible benefits and risks of participating?

There are no benefits or additional risks for participants in this study compared to their usual care, their care teams are collecting the study data.

### Where is the study run from?

Bionical Emas Ltd (UK)

When is the study starting and how long is it expected to run for?  
April 2021 to September 2023

Who is funding the study?  
Kyowa Kirin Ltd (UK)

Who is the main contact?  
Gillian Logan, gillian.logan@kyowakirin.com

## Contact information

### Type(s)

Principal investigator, Scientific, Public

### Contact name

Dr Judith Bubbear

### Contact details

Royal National Orthopaedic Hospital  
Brockley Hill  
Stanmore  
United Kingdom  
HA7 4LP  
+44 (0)20 3947 0056  
judith.bubbear@nhs.net

## Additional identifiers

**Integrated Research Application System (IRAS)**  
321609

**Central Portfolio Management System (CPMS)**  
54855

**Protocol serial number**  
2021-66-UK-CRY

## Study information

### Scientific Title

Early Access experience with burosumab in adults with X-linked hypophosphataemia in the UK: real-world clinical and patient-reported outcomes

### Study objectives

This is a retrospective observational study of patients enrolled in an Early Access Program. This cohort is the first group of adult UK patients to receive burosumab outside a clinical trial. As such it is an opportunity to gain insight into the effectiveness and safety of the medicine in patients under normal clinical care.

## **Ethics approval required**

Ethics approval required

## **Ethics approval(s)**

approved 09/05/2023, East Midlands - Leicester South Research Ethics Committee (Equinox House City Link, Nottingham, NG2 4LA, United Kingdom; +44 (0)207 104 8193; leicestersouth.rec@hra.nhs.uk), ref: 23/EM/0078

## **Study design**

Multicentre single-arm retrospective longitudinal observational study

## **Primary study design**

Observational

## **Study type(s)**

Quality of life, Treatment, Safety

## **Health condition(s) or problem(s) studied**

X-linked hypophosphataemia (XLH)

## **Interventions**

UK centres with patients enrolled in the burosumab Early Access Program are sites in this observational study. Investigators collect data from patients' medical records, including patient-reported outcomes, that were recorded during participants' normal clinical care.

No additional tests or instruments were used for the purposes of this study. Key parameters that will be abstracted, if available, from medical records include:

1. Patient characteristics, demographics and relevant medical history
2. Medications, including analgesics, and treatment history
3. Serum phosphate, alkaline phosphatase, parathyroid hormone, calcium and vitamin D
4. Patient-reported outcomes including Brief Pain Inventory Short Form (BPI), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and EQ-5D-5L
5. Burosumab exposure and adverse events

## **Intervention Type**

Other

## **Primary outcome(s)**

The proportion of adults receiving burosumab for XLH achieving serum phosphate level above the lower limit of normal (according to local reference ranges) in a real-world clinical setting after 6 months' treatment, assessed locally and recorded in medical record

## **Key secondary outcome(s)**

1. Population and clinical characteristics at baseline, including patient-reported outcomes (PROs), recorded in and abstracted from medical records
2. The proportion of adults receiving burosumab for XLH who achieved a serum phosphate level above the lower limit of normal (according to local reference ranges) in a real-world clinical setting at any time, assessed (including vs local reference ranges), recorded in and abstracted from medical records
3. Patient-reported outcomes (where available) change from baseline (start of treatment with burosumab) to 6 months of treatment and 6-monthly thereafter:
  - 3.1. Pain intensity measured by BPI Short Form Q3 (Worst Pain) score

- 3.2. WOMAC stiffness, pain, difficulty performing daily activities, total scores in most bothersome joint
- 3.3. EuroQOL-5-dimension 5 level (EQ-5D-5L)
4. Baseline distribution and changes in the following biochemical measures versus baseline over time:
- 4.1. Serum phosphate, creatinine, alkaline phosphatase (ALP), parathyroid hormone (PTH), calcium, 1,25 dihydroxyvitamin D: routine blood tests carried out during patients' usual clinical care, abstracted from medical records as/when available
- 4.2. Urine calcium and ratio of tubular maximum reabsorption of phosphate to glomerular filtration rate (TmP/GFR): routine urinalysis carried out during patients' usual clinical care, abstracted from medical records as/when available
5. The number and percentage of participants taking opioid, or any pain medication will be summarised at baseline and at 6-monthly intervals. Changes to opioid dose over time will be described. Data from medications/dosing information abstracted from participants' medical records.
6. Impact on ability to work/study will be summarised at baseline and at 6-monthly intervals. Data abstracted from participants' medical records by direct care team, as and when routine care visits happened.
7. Burosumab dosing at baseline, changes over time and total burosumab treatment duration, abstracted from participants' medical records
8. Real-world time to treatment discontinuation (rwTTTD) and description of the reasons, abstracted from participants' medical records, with further information on reasons taken from adverse event reports collected during the Early Access Program.

**Completion date**

31/10/2023

## Eligibility

**Key inclusion criteria**

All participants enrolled in the burosumab early access programme (EAP) will be considered for inclusion

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

18 years

**Upper age limit**

100 years

**Sex**

All

**Total final enrolment**

142

**Key exclusion criteria**

Participants opting out will not have their clinical data collected

**Date of first enrolment**

18/07/2023

**Date of final enrolment**

31/10/2023

**Locations****Countries of recruitment**

United Kingdom

England

**Study participating centre****Royal National Orthopaedic Hospital**

Brockley Hill

Stanmore

England

HA7 4LP

**Study participating centre****University Hospitals Bristol and Weston NHS Foundation Trust**

Trust Headquarters

Marlborough Street

Bristol

England

BS1 3NU

**Study participating centre****Sheffield Teaching Hospitals NHS Foundation Trust**

Northern General Hospital

Herries Road

Sheffield

England

S5 7AU

**Study participating centre**

**University College London Hospitals NHS Foundation Trust**  
250 Euston Road  
London  
England  
NW1 2PG

**Study participating centre**  
**Cambridge University Hospitals NHS Foundation Trust**  
Cambridge Biomedical Campus  
Hills Road  
Cambridge  
England  
CB2 0QQ

## Sponsor information

### Organisation

Kyowa Kirin International (United Kingdom)

### ROR

<https://ror.org/017hh7b56>

## Funder(s)

### Funder type

Industry

### Funder Name

Kyowa Kirin Farmacéutica

### Alternative Name(s)

Kyowa Kirin Farmaceutica SLU, Kyowa Kirin Farmaceutica SL, Kyowa Kirin Farmacéutica S.L.U., ProStrakan, Kyowa Kirin Farmacéutica, S.L.U.

### Funding Body Type

Private sector organisation

### Funding Body Subtype

For-profit companies (industry)

### Location

Spain

# Results and Publications

## Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Data sharing statement to be made available at a later date

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Other files</a>	Patient optout letter version 1.2		01/08/2023	No	No